quark pharmaceuticals inc
Kunshan RiboQuark Receives Series A Funding For QPI-1007
Kunshan RiboQuark Pharmaceutical Technology has raised nearly RMB 45 million in a series A financing round to accelerate the clinical development of QPI-1007.